Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADCT-602 in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
NCT03698552Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2018
- Primary completion
- Nov 2025
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of ADCT-602 in acute lymphoblastic leukemia (ALL), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2018; status: terminated.
02
Drugs
ADCT-602
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03698552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03698552.